Principal Financial Group Inc. Buys 22,000 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Principal Financial Group Inc. grew its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 5.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 423,432 shares of the life sciences company’s stock after buying an additional 22,000 shares during the quarter. Principal Financial Group Inc. owned approximately 0.55% of Integra LifeSciences worth $9,603,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IART. KBC Group NV lifted its holdings in shares of Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after purchasing an additional 2,800 shares during the period. Empowered Funds LLC acquired a new position in shares of Integra LifeSciences during the fourth quarter worth $180,000. Romano Brothers AND Company acquired a new position in shares of Integra LifeSciences during the fourth quarter worth $204,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. acquired a new position in shares of Integra LifeSciences during the fourth quarter worth $204,000. Institutional investors own 84.78% of the company’s stock.

Insider Activity

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on IART shares. Morgan Stanley started coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Citigroup lifted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Price Performance

IART stock opened at $23.21 on Friday. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -257.86, a PEG ratio of 0.73 and a beta of 1.17. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $40.92. The company’s fifty day simple moving average is $23.79 and its 200 day simple moving average is $21.87.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. During the same quarter in the prior year, the business earned $0.89 earnings per share. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. On average, analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.